Café

• 
  The Hardest Sermons You’ll Ever Have To Preach
  Reviewed by Hans Kristensen
• 
  Little Black Books: Science and God
  Reviewed by Andrew Laird
• 
  Making the Most of the Cross
  Reviewed by Lesley Hicks
• 
  Higher Ground
  Reviewed by Andrew Laird

• We’re publishing daily news articles
• Our new home
• Coming soon a new web home for Eternity
• Eyewitness report from Egypt

• Ethical Investment
• Sarah’s Key - the consequences of truth
• Ben Witherington III: Jesus and Women
• Harry Potter’s Critique of Western Extravagance

• The Komen Fiasco's Silver Lining
• The Pink Ribbon and the Dollar Sign
• The Similarities and Differences in Eric Metaxas's and President Obama's Prayer Breakfast Addresses
• The Ironies of Obama's National Prayer Breakfast Speech
• Evangelicals Mounting Concerns over Obama Administration's Contraceptive Mandate

Sometimes money helps

1:00am Tuesday, 11th May 2010  

Lea Carswell

Christian workers’ super is doing something more than giving security. Anglican National Super, which is a signature fund of AMP Capital, has invested in increasing developing nations access to life-saving medicines.
The non-profit Access to Medicine Foundation will release a report in June 2010 ranking pharmaceutical companies on their performance in improving global access to medicines and continued attention on previously neglected diseases, some as basic as infection caused by the common hookworm.
Wim Leereveld, chairman of the Access to Medicine Foundation which is based in The Netherlands, will present the report, highlighting a simple theme, “4.8 billion people have access to medicine; 2 billion to go.”
AMP Capital, which includes Anglican National Super, is one of seventeen global institutional investors behind the Index and the only company from Australia.
“The Index is a very useful reference indicator for our ethical investment strategy, in addition to our own screening methodology,” said Angus Dennis, Senior Investment Specialist, AMP Capital Investors.
“The Access to Medicine Index forces companies to look at issues they may not otherwise consider a priority,” he continued. “It judges companies on seven key technical areas—like how much development they channel to treating neglected world diseases, their approach to non-exclusive voluntary licensing, how affordable their medicines are for those in need or how serious is their commitment to l product donations.”